Millendo Therapeutics develops           novel, disease-modifying treatments         for endocrine diseases caused by   hormone dysregulation.

Learn More

June 23, 2016
Millendo Therapeutics Appoints New Independent Board Member and Names Chairperson of the Board
Read More >>

June 8, 2016
Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Congenital Adrenal Hyperplasia
Read More >>